Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02434445

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hepatorenal Syndrome Digestive System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Liver Diseases Male Urogenital Diseases Urogenital Diseases Urologic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
  • Willing to give informed consent

Exclusion criteria

  • Patients with co-existing renal diseases

Treatment and study plan

Primary outcomes

  1. Hepatorenal syndrome

    Time frame: 12 weeks

Secondary outcomes

  1. Mortality

    Time frame: 6 months

  2. Chronic renal impairment

    Time frame: 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Desmond Yap, MD

CONTACT

[email protected]

85222553879

Sponsors and collaborators

Lead sponsor

The University of Hong Kong

Other

Collaborators

  • The Hong Kong Society of Nephrology

Registry information

Important dates

Study start
2012
Primary completion
2028
Study completion
2028
First posted
May 5, 2015
Registry last updated
Dec 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.